Findings
SECONDARY
In this secondary analysis of a phase 3 clinical trial with 350 participants, significant factors associated with shorter time to PSA failure were younger than 70 years, a PSA of 10 ng/mL or more, and a Gleason score of 8 to 10. A high-risk group, defined by these 3 factors, had 43.8% risk of PSA failure at 3 years.